Processa Pharmaceuticals Inc (PCSA) — Cash Flow-to-Debt Ratio
Processa Pharmaceuticals Inc (PCSA) has a Cash Flow-to-Debt Ratio of -1.30x as of December 2025, meaning its operating cash flow of $-2.90 Million could theoretically repay -1% of its total liabilities ($2.24 Million) in one year. See PCSA cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Processa Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Processa Pharmaceuticals Inc across 15 annual periods. Also explore Processa Pharmaceuticals Inc annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Processa Pharmaceuticals Inc (2011–2025)
Year-by-year debt coverage analysis for Processa Pharmaceuticals Inc. For market capitalisation and broader financial context, see market value of Processa Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.09x | $-11.39 Million | $2.24 Million | ▲ +30.6% |
| 2024 | -7.33x | $-11.25 Million | $1.53 Million | ▲ +27.5% |
| 2023 | -10.11x | $-8.06 Million | $797.48K | ▼ -21.0% |
| 2022 | -8.36x | $-9.61 Million | $1.15 Million | ▲ +6.2% |
| 2021 | -8.91x | $-8.72 Million | $978.40K | ▼ -544.8% |
| 2020 | -1.38x | $-3.14 Million | $2.27 Million | ▼ -44.2% |
| 2019 | -0.96x | $-2.75 Million | $2.87 Million | ▲ +9.2% |
| 2018 | -1.06x | $-3.71 Million | $3.51 Million | ▼ -66.4% |
| 2017 | -0.63x | $-1.65 Million | $2.61 Million | ▼ -51.5% |
| 2016 | -0.42x | $-871.91K | $2.08 Million | ▲ +0.0% |
| 2015 | -0.42x | $-871.91K | $2.08 Million | ▲ +79.3% |
| 2014 | -2.02x | $-2.70 Million | $1.33 Million | ▼ -0.8% |
| 2013 | -2.00x | $-2.54 Million | $1.27 Million | ▼ -40.4% |
| 2012 | -1.43x | $-1.89 Million | $1.32 Million | ▼ -408.7% |
| 2011 | -0.28x | $-710.00K | $2.53 Million | — |